Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Glabridin ameliorates DNFB-induced atopic dermatitis by suppressing MAPK/NF-κB signaling pathways in mice

Lu Cheng1, Chuanqi Huang1, Xin Xiong1, Jie Jiang1, Fuqian Wang1, Dan Zhang1, Shuting Liu2, Yan Feng3, Song Hu1 , Hong Zhang1

1Department of Pharmacy, Wuhan No. 1 Hospital (Wuhan Hospital of Traditional and Western Medicine), Wuhan, China; 2Department of Dermatology, Wuhan No. 1 Hospital (Wuhan Hospital of Traditional and Western Medicine), Wuhan, China; 3Department of Pathology, Wuhan No. 1 Hospital (Wuhan Hospital of Traditional and Western Medicine), Wuhan, China.

For correspondence:-  Song Hu   Email: huyaoshi@sina.com

Accepted: 27 February 2023        Published: 31 March 2023

Citation: Cheng L, Huang C, Xiong X, Jiang J, Wang F, Zhang D, et al. Glabridin ameliorates DNFB-induced atopic dermatitis by suppressing MAPK/NF-κB signaling pathways in mice. Trop J Pharm Res 2023; 22(3):525-533 doi: 10.4314/tjpr.v22i3.9

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the anti-inflammatory mechanism of action of glabridin (GBD) isolated from glycyrrhizae radix et rhizoma (Glycyrrhiza glabra L.) using atopic dermatitis (AD) mouse model.
Methods: Nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways were investigated. The dorsal skin and serum of 2,4-dinitrofluorobenzene (DNFB)-induced AD mice were used to determine the levels of various inflammatory cytokines, including interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-4, IL-5, IL-6, IL-13, and immunoglobulin E (IgE) by enzyme-linked immunosorbent assay (ELISA). The relative levels of inflammation-associated mRNA and signaling pathways were determined by real time-polymerase chain reaction (RT-PCR) and western blotting, respectively. Hematoxylin and eosin (H&E) staining was used to assess the effect of GBD on tissue thickening and inflammatory cell infiltration in mice with AD.
Results: Glabridin significantly relieved dorsal skin thickening, scabbing, and bleeding, and reduced the infiltration of inflammatory cells in mice with AD (p < 0.05). The levels of IFN-γ, TNF-α, IL-4, IL-5, IL-6, IL-13, and IgE were significantly reduced (p < 0.05 or 0.01). Moreover, the relative levels of IL-6 and IFN-γ mRNA showed a significant decrease (p < 0.01). Furthermore, GBD inhibited phosphorylation of MAPK signaling pathway and activation of NF-κB (p < 0.05 or 0.01).
Conclusion: Glabridin exerts an inhibitory effect on AD by blocking MAPK and NF-κB signaling pathways. This finding highlights the relationship between traditional Chinese medicine and modern AD therapeutic methods, which should be further investigated for its potential to be developed as an external anti-AD medicine.

Keywords: Glycyrrhizae radix et rhizome, Glycyrrhiza glabra, Atopic dermatitis, Traditional Chinese Medicine, Inflammation

Impact Factor
Thompson Reuters (ISI): 0.523 (2021)
H-5 index (Google Scholar): 39 (2021)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates